ARA-290
- Category
- Immune & Defense
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
An erythropoietin-derived peptide engineered to spur nerve and tissue repair without raising red blood cell counts, marketed for neuropathic pain and diabetic metabolic support. Evidence rests on Phase 2 trials showing gains in nerve density, pain, and HbA1c, but no Phase 3 data exists and long-term safety is unknown. One trial had serious adverse events including an unrelated death, and non-trial supply is unregulated. Not FDA-approved; banned by WADA.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide designed to mimic the tissue-protective effects of erythropoietin (EPO) — the hormone known for boosting red blood cell production — without actually affecting blood cell counts. It selectively activates a repair receptor found on nerve cells, blood vessel cells, and immune cells, promoting tissue protection, reducing inflammation, and stimulating nerve fiber regeneration. Developed by Araim Pharmaceuticals, it has received FDA Fast Track and Orphan Drug designations for sarcoidosis-related nerve damage.
How it works in the body
Binds to a special receptor formed when the erythropoietin receptor pairs with the beta common receptor (IRR). This triggers anti-inflammatory and tissue-protective signaling in nerves and tissues without stimulating red blood cell production, making it distinct from EPO.
Research overview
ARA-290 works by activating the innate repair receptor (IRR), triggering protective and regenerative responses in damaged tissues — particularly small nerve fibers. In a Phase 2b study of 64 sarcoidosis patients, the optimal dose (4 mg daily for 28 days) produced a 23% increase in corneal nerve fiber area, a direct measure of small nerve regeneration. In a separate trial with 48 type 2 diabetes patients, the same dose significantly improved blood sugar control (HbA1c), neuropathic pain scores, and cholesterol levels. It also blocks TRPV1 pain receptors, contributing to its pain-relieving effects. The compound has received multiple regulatory designations including US and EU Orphan Drug status for sarcoidosis and FDA Fast Track for sarcoidosis-related small fiber neuropathy. Araim Pharmaceuticals has completed an end-of-Phase 2 FDA meeting and has indicated plans for Phase 3 trials. Evidence quality is moderate — multiple small Phase 2 trials show consistent benefits, but large Phase 3 confirmatory trials have not yet been completed.
Who researches ARA-290?
Commonly researched by
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(8)
Rated by level of concern
Not approved by any regulatory agency — quality and purity of non-clinical-trial sources cannot be guaranteed
HighEMA orphan designation register EU/3/16/1721 (designation only); no FDA/EMA marketing authorization on record
Prohibited by WADA — use may result in anti-doping violations for competitive athletes
HighWADA World Anti-Doping Code International Standard Prohibited List, section S2.1 (innate repair receptor agonists) — https://www.wada-ama.org/en/prohibited-list
Investigational compound — long-term safety profile not established; no Phase 3 data available
HighPMID 28475703; PMID 25387363; PMID 24136731; PMID 23168581; PMID 32674280 (Phase 1/2 reports)
Serious adverse events in Phase 2 diabetes trial: 4 SAEs including 1 renal insufficiency event (possibly related) and 1 fatal myocardial infarction (judged unrelated by safety committee)
ModeratePMID 25387363 (Mol Med 2015, safety section)
No long-term carcinogenicity or reproductive toxicity data available
ModerateExclusion criteria in PMID 24136731 and PMID 25387363; absence of any published tox study in PubMed
Potential immune modulation effects — caution advised when combining with immunosuppressants or biologic anti-inflammatory drugs
TheoreticalPMID 24136731 (exclusion criteria); PMID 25728128 (IRR biology review)
Injection site reactions (mild) reported in clinical trials
TheoreticalPMID 24136731 (safety section, explicitly reports absence of injection-site pain or irritation); PMID 25387363
Headache reported as a common mild adverse event
TheoreticalNo primary source itemizing headache; PMID 24136731 and PMID 25387363 AE reporting reviewed and do not support it
Interaction summary(8)
Rated by direction with this peptide
Loop diuretics (furosemide) and other agents in patients with pre-existing renal impairment
CautionLowSeverity reduced from Moderate: this rests on a single confounded case. In the Phase 2 diabetes trial, one subject whose furosemide dose was increased mid-trial had borderline renal insufficiency worsen (creatinine ~119 to ~159 umol/L) without recovery after ARA-290 was stopped while furosemide continued — a pattern at least as consistent with diuretic-driven prerenal decline as with study drug. No pharmacokinetic or interaction study exists. It is the only renal signal in the entire human record, so it justifies renal monitoring when baseline function is borderline, but it does not support asserting a moderate-severity interaction.
PMID 25387363 (Mol Med 2015, safety section)
Insulin, sulfonylureas and other glucose-lowering agents
CautionLowARA-290 produced a small placebo-controlled HbA1c reduction (-0.21% at day 56, P=0.002) that persisted about a month after dosing stopped, so additive glucose lowering on top of an intensive regimen is mechanistically plausible and periodic glucose monitoring is reasonable. The effect is very small, it comes from one unreplicated Phase 2 trial, and no hypoglycemia signal was reported even though subjects continued their full diabetes regimens throughout.
PMID 25387363
Erythropoiesis-stimulating agents (epoetin, darbepoetin, CERA)
NeutralTheoreticalARA-290 acts at the EPOR-betacommon innate repair receptor rather than the EPOR homodimer, and human trials showed no clinically significant hematologic change and no anti-drug antibodies, so no additive erythropoietic or thrombotic interaction is expected on mechanism. The two have never been co-administered in any study, so this is expectation rather than evidence. Both fall within the same WADA prohibited class.
PMID 25387363; PMID 24136731; PMID 25728128
Neuropathic pain medications (opioids, gabapentinoids, tricyclics, SNRIs, NSAIDs, antiepileptics)
NeutralLowIn the Phase 2 diabetes RCT subjects remained on a wide range of these agents throughout dosing and follow-up with no reported interaction, so concurrent use is the studied condition rather than an untested one — ARA-290 was evaluated as an add-on, never as a replacement. No formal interaction study was performed, and concomitant-medication tolerance in a small trial is weak evidence of safety, not proof of none.
PMID 25387363 (concomitant medication reporting)
Systemic corticosteroids and conventional immunosuppressants (in sarcoidosis)
NeutralLowSarcoidosis patients on stable background immunosuppression were enrolled and treated in the ARA-290 trials without reported interaction or loss of effect, which is consistent with the mechanistic claim that IRR agonism is tissue-protective rather than immunosuppressive. No formal interaction study exists and the numbers involved are small.
PMID 24136731; PMID 23168581
Anti-TNF biologics (infliximab, adalimumab, etanercept)
CautionTheoreticalThere is no interaction data at all: the sarcoidosis trials excluded anyone who had received anti-TNF therapy in the preceding months, so combined use is simply unstudied. The exclusion itself signals investigator caution about overlapping anti-inflammatory pathways, but no clinical consequence has ever been demonstrated in either direction.
PMID 24136731 (exclusion criteria)
Statins and other lipid-lowering therapy
NeutralTheoretical'synergistic' asserts a combination effect that has never been tested. What actually exists: in one small Phase 2 trial, ARA-290 improved the cholesterol/HDL ratio (P=0.039) and triglycerides (P=0.043) as secondary endpoints while patients remained on their existing regimens, which shows only that the lipid change was observed on a statin background, not that the two act additively or synergistically. No adverse interaction is expected or reported either.
PMID 25387363
Vaccination / recent immunization
CautionTheoreticalThe sarcoidosis trial protocol excluded subjects vaccinated or immunized within the preceding months, so the effect of IRR agonism on vaccine-induced immune responses is entirely unstudied. No clinical consequence has been demonstrated in either direction; this is an unstudied combination, not an observed risk.
PMID 24136731 (exclusion criteria)
Known risks(8)
Investigational compound — long-term safety profile not established; no Phase 3 data available
Injection site reactions (mild) reported in clinical trials
Headache reported as a common mild adverse event
Serious adverse events in Phase 2 diabetes trial: 4 SAEs including 1 renal insufficiency event (possibly related) and 1 fatal myocardial infarction (judged unrelated by safety committee)
Potential immune modulation effects — caution advised when combining with immunosuppressants or biologic anti-inflammatory drugs
No long-term carcinogenicity or reproductive toxicity data available
Not approved by any regulatory agency — quality and purity of non-clinical-trial sources cannot be guaranteed
Prohibited by WADA — use may result in anti-doping violations for competitive athletes
Drug interactions(5)
Immunosuppressants (e.g., methotrexate, cyclosporine, tacrolimus)
Moderate — use with caution under medical supervisionPotential amplification of immune modulation; ARA-290 has anti-inflammatory properties that may compound with immunosuppressive effects
Biologic anti-inflammatory agents (e.g., TNF inhibitors, IL-6 inhibitors)
Moderate — caution advised; no formal interaction studies conductedOverlapping anti-inflammatory mechanisms may increase risk of infection or excessive immune suppression
Erythropoiesis-stimulating agents (EPO, darbepoetin)
Low — theoretical concern; ARA-290 does not have erythropoietic activityTheoretical competition for EPO receptor binding sites on the innate repair receptor complex; clinical significance unknown
TRPV1 agonists (e.g., capsaicin topical preparations)
Low — pharmacodynamic interaction; clinical relevance not establishedARA-290 antagonizes TRPV1; concurrent TRPV1 agonist use may reduce efficacy of either compound
Nephrotoxic drugs (e.g., NSAIDs, aminoglycosides)
Moderate — monitor renal functionOne case of renal insufficiency was reported in a patient on furosemide during ARA-290 treatment; exercise caution with nephrotoxic combinations
Research & benefits
Evidence base
- Evidence Level
- Early Clinical (Phase I/II)
- Total Studies
- 15
- Human Studies
- 6
Researched for(8)
Rated by confidence in the evidence
Regenerates small nerve fibers, shown as increased corneal nerve fiber area in a Phase 2 trial
MediumSmall placebo-controlled trial found increased corneal nerve fiber area at 4 mg dose in sarcoidosis patients.
PMID 28475703 (Invest Ophthalmol Vis Sci 2017) is the primary source: a placebo-controlled Phase 2b trial in sarcoidosis-associated small nerve fiber neuropathy showing a significant placebo-corrected increase in corneal nerve fiber area of 697 um2 at the 4 mg dose (p=0.012); this is the only dose that reached significance. PMID 24136731 (Mol Med 2013) is an earlier open-label pilot in the same population and same peptide showing a corroborating 14.5% increase from baseline.
Reduces neuropathic pain — significant improvements in PainDetect and SFNSL scores in both sarcoidosis and diabetic neuropathy patients
MediumHuman trials show pain score gains, but the largest trial's effect missed significance.
PMID 25387363; PMID 24136731; PMID 23168581; PMID 28475703
Improves metabolic control — significant reductions in HbA1c (p=0.002), cholesterol/HDL ratio (p=0.039), and triglycerides (p=0.043) in diabetic patients
MediumSingle small trial found improved HbA1c, cholesterol ratio, and triglycerides in diabetics.
PMID 25387363 (Mol Med 2015)
Anti-inflammatory effects without immunosuppression — reduces pro-inflammatory cytokine signaling via innate repair receptor activation
LowMechanism and animal data only, no human trial has shown reduced inflammatory markers.
PMID 25728128 (Brines & Cerami, Pharmacol Ther 2015); PMID 25387363
Tissue cytoprotection — activates endogenous repair pathways through the innate repair receptor (IRR) on endothelial cells, glia, and immune cells
LowExtensive animal data across injury models, no human tissue-protection endpoint tested.
PMID 25728128 (Pharmacol Ther 2015); preclinical models cited within PMID 25387363
No erythropoietic activity — engineered to avoid EPO-related risks (polycythemia, hypertension, thrombosis)
HighMultiple human RCTs found no erythropoietic changes over 28 days of dosing.
PMID 25387363; PMID 24136731; PMID 23168581; PMID 32674280 (A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema, J Clin Med 2020)
Improves quality of life — significant improvements in physical role functioning (p=0.05) and vitality (p=0.02) on RAND-36/SF-36
LowUncontrolled within-group score changes, not tested against placebo directly.
PMID 25387363 (RAND-36 data); PMID 23168581 (SF-36 subdomains)
Potential pancreatic islet graft protection — EU orphan designation for prevention of graft loss in islet transplantation
SpeculativeEU orphan designation granted, based on preclinical islet studies, no human efficacy data.
EMA orphan designation register, EU/3/16/1721 (https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1721)
Benefits(8)
Regenerates small nerve fibers, shown as increased corneal nerve fiber area in a Phase 2 trial
Reduces neuropathic pain — significant improvements in PainDetect and SFNSL scores in both sarcoidosis and diabetic neuropathy patients
Improves metabolic control — significant reductions in HbA1c (p=0.002), cholesterol/HDL ratio (p=0.039), and triglycerides (p=0.043) in diabetic patients
Anti-inflammatory effects without immunosuppression — reduces pro-inflammatory cytokine signaling via innate repair receptor activation
Tissue cytoprotection — activates endogenous repair pathways through the innate repair receptor (IRR) on endothelial cells, glia, and immune cells
No erythropoietic activity — engineered to avoid EPO-related risks (polycythemia, hypertension, thrombosis)
Improves quality of life — significant improvements in physical role functioning (p=0.05) and vitality (p=0.02) on RAND-36/SF-36
Potential pancreatic islet graft protection — EU orphan designation for prevention of graft loss in islet transplantation
Key studies(5)
Heij L, Niesters M, Swartjes M, et al.
Molecular Medicine
2012
ARA-290 significantly reduced neuropathic symptoms in sarcoidosis patients (SFNSL -11.5 vs -2.9, p<0.05) with no safety concerns
Brines M, et al.
Molecular Medicine
2015
ARA-290 (4 mg SC daily x28 days) significantly improved HbA1c (p=0.002), neuropathic pain (p=0.037), and corneal nerve fiber density (p=0.02) in type 2 diabetes patients
Culver DA, Dahan A, Bajorunas D, et al.
Investigative Ophthalmology & Visual Science (IOVS)
2017
Phase 2b: 4 mg cibinetide SC daily for 28 days produced ~23% increase in corneal nerve fiber area in 64 sarcoidosis patients
Zhang W, Yu G, Zhang M.
Peptides
2016
Demonstrated that ARA-290 antagonizes TRPV1 channels, providing both disease-modifying and analgesic mechanisms
Araim Pharmaceuticals
2014
Phase 2b trial registration for dose-ranging study in sarcoidosis-associated small fiber neuropathy
Regulation & availability
Why researchers look at it
In a Phase 2b trial of 64 sarcoidosis patients, the optimal dose produced a 23% increase in corneal nerve fiber area — one of the few demonstrated cases of actual nerve regeneration in a clinical setting. A separate trial in 48 type 2 diabetes patients showed significant improvements in HbA1c, neuropathic pain, and cholesterol. The FDA has granted Fast Track and Orphan Drug designations, and if Phase 3 confirms Phase 2 results, ARA-290 could become the first therapy specifically approved for small fiber neuropathy.
- Estimated cost
- Not yet available — investigational
- FDA status
- Investigational New Drug (IND). Not FDA-approved for any indication. Has received: (1) FDA Orphan Drug Designation for treatment of sarcoidosis (2016); (2) FDA Fast Track Designation for sarcoidosis-associated small fiber neuropathy (2014); (3) FDA Orphan Drug Designation for pancreatic islet transplantation graft survival; (4) EU Orphan Medicinal Product designations for sarcoidosis and pancreatic islet transplantation. Completed end-of-Phase 2 FDA meeting with plans for Phase 3 development.
- WADA status
- Prohibited — ARA-290 is banned by the World Anti-Doping Agency (WADA) under substances related to EPO-derived peptides with tissue-repair and potential performance-enhancing properties. Athletes subject to anti-doping regulations must not use this compound.
- Prescribability
- ARA-290 is not FDA-approved and is not eligible for compounding: FDA found that its nomination for the compounding list lacked adequate support (Category 3). Clinical use requires an authorized investigational pathway.
- Availability
- Not commercially available as an approved pharmaceutical. Available through clinical trials conducted by Araim Pharmaceuticals; human use remains investigational. Its current 503A Category 3 listing does not provide a routine compounding pathway, and physician supervision does not change that status. Not available as a standard prescription medication.
International status
EU
Not approved
US
Not FDA-approved
Worldwide
No regulatory approval in any jurisdiction
Regulatory timeline(10)
- 2012Phase 2 pilot study completed — ARA-290 (2 mg IV 3x/week) in sarcoidosis SFN (n=22); published in Molecular Medicine
- 2014Phase 2 trial in type 2 diabetes (NTR3858) completed — ARA-290 (4 mg SC daily x28 days, n=48)
- 2014FDA Fast Track Designation granted for sarcoidosis-associated small fiber neuropathy
- 2014Phase 2 diabetes trial results published in Molecular Medicine (Brines et al.)
- 2016FDA Orphan Drug Designation granted for treatment of sarcoidosis
- 2016EU Orphan Medicinal Product designation granted for prevention of graft loss in pancreatic islet transplantation
- 2016FDA Orphan Drug Designation granted for pancreatic islet transplantation graft survival
- 2017Phase 2b dose-ranging study (1, 4, 8 mg SC daily, n=64) results published; 4 mg identified as optimal dose
- 2017End-of-Phase 2 meeting completed with FDA; Phase 3 development plans announced for sarcoidosis neuropathy and diabetic neuropathy
- 2026 (current)No Phase 3 trial results publicly reported; ARA-290 remains investigational with no marketing approval in any jurisdiction
Sources & FAQs
Research sources(10)
- Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy
- ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes
- Safety and Efficacy of ARA 290 in Sarcoidosis — Pilot Study
- Cibinetide Improves Corneal Nerve Fiber Abundance in Sarcoidosis-Associated Small Nerve Fiber Loss
- Study of Efficacy of ARA 290 on Corneal Nerve Fiber Morphology and Function
- ARA 290 relieves pathophysiological pain by targeting TRPV1 channel
- Araim Pharmaceuticals Receives Orphan Drug Designation from the US FDA for ARA 290
- Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290
- EU Orphan Designation for Prevention of Graft Loss in Pancreatic Islet Transplantation
- Cibinetide — Completed Phase 2 Trials
Frequently asked questions(6)
What is ARA-290 and how does it differ from EPO?
ARA-290 (cibinetide) is an 11-amino acid synthetic peptide derived from the tissue-protective region of erythropoietin (EPO). Unlike EPO, it does not stimulate red blood cell production, avoiding risks of polycythemia, hypertension, and thrombosis. It selectively activates the innate repair receptor (IRR) for tissue protection and repair.
What conditions is ARA-290 being studied for?
Primary clinical development targets sarcoidosis-associated small fiber neuropathy and diabetic peripheral neuropathy. Preclinical research has also explored applications in pancreatic islet transplantation, chronic pain, wound healing, and neuroinflammation.
How is ARA-290 administered?
In clinical trials, ARA-290 was administered either intravenously (in early studies) or by subcutaneous injection (in later Phase 2 studies).
Is ARA-290 FDA-approved?
No. ARA-290 remains an investigational drug. It has received FDA Orphan Drug and Fast Track designations for sarcoidosis-associated neuropathy, but has not completed Phase 3 trials or received marketing approval in any country.
What are the main side effects?
In clinical trials, ARA-290 was generally well tolerated. Common mild side effects included headache and injection site reactions. No dose-limiting toxicities were observed. One trial reported 4 serious adverse events in the treatment arm, including a fatal MI in a 70-year-old patient judged unrelated to the drug by the safety committee.
Can athletes use ARA-290?
No. ARA-290 is prohibited by the World Anti-Doping Agency (WADA) as it falls under substances with tissue-repair and potentially performance-enhancing properties related to EPO-derived peptides.